Charles W. Newhall III, a director at Supernus Pharmaceuticals, Inc. ($SUPN), sold shares on the open market five times over the past year, totaling about $1.5 million. His most recent sale occurred on October 9, 2025. These $SUPN insider sales rank 4,002nd among 11,678 individual insiders in our database, where the average is $8.6 million across about 6.4 transactions. Newhall made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 24, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | D | Restricted Stock Unit | 4475 | $0.00 | 0.0000 | 56,552,741 | 100.00% | 0.01% |
| Feb. 24, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | A | Common Stock | 4475 | $0.00 | 124,119.0000 | 56,552,741 | 3.74% | 0.01% |
| Feb. 18, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | A | Director Stock Option (Right to Buy) | 4977 | $0.00 | 4,977.0000 | 56,552,741 | 9999.99% | 0.01% |
| Feb. 18, 2026 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | A | Restricted Stock Unit | 2989 | $0.00 | 2,989.0000 | 56,552,741 | 9999.99% | 0.01% |
| Nov. 21, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | M | Common Stock | 15000 | $12.98 | 119,644.0000 | 56,552,741 | 14.33% | 0.03% |
| Nov. 21, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | M | Director Stock Option (Right to Buy) | 15000 | $0.00 | 0.0000 | 56,552,741 | 100.00% | 0.03% |
| Oct. 9, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | S | Common Stock | 1200 | $51.55 | 104,644.0000 | 56,552,741 | 1.13% | 0.00% |
| Oct. 9, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | S | Common Stock | 23800 | $50.73 | 105,844.0000 | 56,552,741 | 18.36% | 0.04% |
| Aug. 27, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | S | Common Stock | 3588 | $45.01 | 129,644.0000 | 55,958,537 | 2.69% | 0.01% |
| Aug. 25, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | S | Common Stock | 1000 | $45.00 | 133,232.0000 | 55,958,537 | 0.74% | 0.00% |
| Aug. 22, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | S | Common Stock | 1412 | $45.00 | 134,232.0000 | 55,958,537 | 1.04% | 0.00% |
| Feb. 22, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | A | Common Stock | 5369 | $0.00 | 135,644.0000 | 55,958,537 | 4.12% | 0.01% |
| Feb. 22, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | D | Restricted Stock Units | 5369 | $0.00 | 0.0000 | 55,958,537 | 100.00% | 0.01% |
| Feb. 19, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | A | Director Stock Option (Right to Buy) | 7296 | $0.00 | 7,296.0000 | 55,958,537 | 9999.99% | 0.01% |
| Feb. 19, 2025 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | A | Restricted Stock Unit | 4475 | $0.00 | 4,475.0000 | 55,958,537 | 9999.99% | 0.01% |
| Nov. 11, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | S | Common Stock | 10700 | $36.24 | 130,275.0000 | 56,016,350 | 7.59% | 0.02% |
| Nov. 11, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | M | Director Stock Option (Right to Buy) | 20000 | $0.00 | 0.0000 | 56,016,350 | 100.00% | 0.04% |
| Nov. 11, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | M | Common Stock | 20000 | $9.13 | 140,975.0000 | 56,016,350 | 16.53% | 0.04% |
| Feb. 23, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | D | Restricted Stock Unit | 3886 | $0.00 | 0.0000 | 55,506,828 | 100.00% | 0.01% |
| Feb. 23, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | A | Common Stock | 3886 | $0.00 | 120,975.0000 | 55,506,828 | 3.32% | 0.01% |
| Feb. 22, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | A | Restricted Stock Units | 5369 | $0.00 | 5,369.0000 | 55,506,828 | 9999.99% | 0.01% |
| Feb. 22, 2024 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | A | Director Stock Option (Right to Buy) | 8252 | $0.00 | 8,252.0000 | 55,506,828 | 9999.99% | 0.01% |
| Nov. 16, 2023 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | M | Director Stock Option (Right to Buy) | 7457 | $0.00 | 0.0000 | 61,679,800 | 100.00% | 0.01% |
| Nov. 16, 2023 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | M | Common Stock | 7457 | $9.24 | 119,589.0000 | 61,679,800 | 6.65% | 0.01% |
| Nov. 16, 2023 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | S | Common Stock | 2500 | $28.01 | 117,089.0000 | 61,679,800 | 2.09% | 0.00% |
| Feb. 23, 2023 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | A | Director Stock Option (Right to Buy) | 6293 | $0.00 | 6,293.0000 | 61,679,800 | 9999.99% | 0.01% |
| Feb. 23, 2023 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | A | Restricted Stock Units | 3886 | $0.00 | 3,886.0000 | 61,679,800 | 9999.99% | 0.01% |
| Feb. 22, 2023 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | A | Common Stock | 3882 | $0.00 | 112,132.0000 | 61,679,800 | 3.59% | 0.01% |
| Feb. 22, 2023 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | D | Restricted Stock Units | 3882 | $0.00 | 0.0000 | 61,679,800 | 100.00% | 0.01% |
| April 17, 2018 | SUPERNUS PHARMACEUTICALS, INC. | $SUPN | NEWHALL CHARLES W III | Director | G | Common Stock | 2203 | $0.00 | 108,250.0000 | 0 | 1.99% | 0.00% |